Ernexa Therapeutics Inc. Total Long-Term Debt
Ernexa Therapeutics Inc. (ERNA) had Total Long-Term Debt of $725.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2020-11-13
- 2020-09-30: Long-term Debt $725.00K.
- 2020-06-30: Long-term Debt $1.63M.
- 2018-12-31: Long-term Debt $3.75M.
- 2017-12-31: Long-term Debt $5.12M.
| Period end | Long-term Debt |
|---|---|
| 2020-09-30 | $725.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $1.63M 10-Q · filed 2020-08-07 |
| 2018-12-31 | $3.75M 10-K · filed 2019-03-22 |
| 2017-12-31 | $5.12M 10-K · filed 2018-03-09 |
| 2016-12-31 | $8.11M 10-K · filed 2017-03-09 |
| 2015-12-31 | $7.44M 10-K · filed 2016-03-15 |
| 2014-12-31 | $5.32M 10-K · filed 2015-03-27 |
| 2013-12-31 | $1.59M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |